Caplin Steriles (Caplin), a subsidiary of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Phenylephrine hydrochloride Ophthalmic Solution USP 2.5% and 10% (eye drops), a generic therapeutic equivalent version of the Reference Listed Drug (RLD), from Alcon Research LLC. Phenylephrine hydrochloride Ophthalmic Solution USP 2.5% and 10% is indicated to dilate the pupil of the eyes. According to IQVIATM (IMS Health), Phenylephrine hydrochloride Ophthalmic Solution USP 2.5% and 10% had US sales of approximately $32 million for the 12-month period ending Mar 2024Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 19.08% to Rs 121.59 crore in the quarter ended March 2024 as against Rs 102.11 crore during the previous quarter ended March 2023. Sales rose 16.43% to Rs 453.22 crore in the quarter ended March 2024 as against Rs 389.28 crore during the previous quarter ended March 2023.For the full year,net profit rose 21.48% to Rs 457.08 crore in the year ended March 2024 as against Rs 376.26 crore during the previous year ended March 2023. Sales rose 15.50% to Rs 1694.10 crore in the year ended March 2024 as against Rs 1466.73 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales453.22389.28 16 1694.101466.73 16 OPM %32.0431.84 -32.5530.07 - PBDT162.43135.20 20 617.87496.34 24 PBT146.03124.07 18 564.43451.35 25 NP121.59102.11 19 457.08376.26 21 Powered by Capital Market - Live News

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 16 May 2024, has recommended a Interim dividend of Rs.2.5 per share (i.e.125%), subject to the approval of the shareholders.Powered by Capital Market - Live News

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 16 May 2024Powered by Capital Market - Live News

Caplin Point Laboratories has received Colombia`s INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on 03 May and found compliant as per INVlMA`s norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).Powered by Capital Market - Live News